Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 plus carboplatin and etoposide versus placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer
CTR20182176Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Hengrui Therapeutics. Started Dec 2018; status: active.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20182176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182176.